【摘要】：目的:系統(tǒng)評價奧曲肽與硬化療法治療肝硬化食管靜脈曲張出血的療效。 方法:計算機檢索Pubmed數(shù)據(jù)庫（1966--2013.12）、 Embase數(shù)據(jù)庫（1974--2013.12）、Cochrane圖書館對照試驗的中心資料庫（2013.12）、萬方數(shù)據(jù)庫（1998--2013.12）、相關期刊論文（CNKI，，1979--2013.12）。收集奧曲肽與硬化療法治療肝硬化食管靜脈曲張出血的隨機對照試驗（RCT）。用Cochrane圖書館的RevMan5.2軟件進行meta分析。 結果:共納入8篇文獻，包括1078例患者，奧曲肽組（試驗組）540例，硬化療法組（對照組）538例，其中A級文獻3篇，B級文獻5篇。meta分析結果顯示，奧曲肽組治療食管靜脈曲張出血在早期止血率、再出血率（療程內(nèi)）、再出血率（42日內(nèi)）、病死率（療程內(nèi)）、病死率（42日內(nèi)）、不良反應發(fā)生率方面與硬化療法組相比無統(tǒng)計學差異。合并優(yōu)勢比（OR）分別為1.20（95%CI為0.83~1.73，P=0.33）；1.16（95%CI為0.74~1.83，P=0.52）；0.80（95%CI為0.58~1.10，P=0.17）；1.15（95%CI為0.66~2.00，P=0.61）；1.11（95%CI為0.76~1.62，P=0.59）；0.46（95%CI為0.13~1.55，P=0.21）。采用RevMan5.2軟件繪制倒漏斗圖，除了再出血率（42日內(nèi)）其余所有結果顯示圖形基本對稱，提示文獻發(fā)表偏倚可能性小。將每個研究逐一排除后的meta分析顯示匯總靈敏度和特異度未見明顯改變，說明納入文獻的穩(wěn)定性好。 結論:奧曲肽組和硬化療法組治療肝硬化食管靜脈曲張出血，在早期止血率、再出血率、病死率及不良反應發(fā)生率方面并無統(tǒng)計學差異。在治療肝硬化食管靜脈曲張出血方面，硬化療法并不優(yōu)于奧曲肽治療。
[Abstract]:Objective: to evaluate the efficacy of octreotide and sclerotherapy in the treatment of esophageal variceal hemorrhage due to cirrhosis. Methods: the Pubmed database (1966-2013.12), Embase database) (1974-2013.12), Cochrane library control database (2013.12), Wanfang database (1998-2013.12) was searched by computer. Full text Database of Chinese Journals (CNKI,1979--2013.12). Collection of octreotide and sclerotherapy in the treatment of cirrhosis esophageal variceal hemorrhage: a randomized controlled trial (RCT). Meta analysis is carried out with RevMan5.2 software of Cochrane library. Results: a total of 8 articles were included, including 1078 patients, 540 octreotide group (trial group) and 538 sclerotherapy group (control group), including 3 A literature and 5 B literature. The results of meta analysis showed that. In octreotide group, the early hemostasis rate, rebleeding rate (within course of treatment), rebleeding rate (within 42 days), death rate (within course of treatment), mortality rate (within 42 days) in the treatment of esophageal variceal bleeding were observed. There was no significant difference in the incidence of adverse reactions between the sclerotherapy group and the sclerotherapy group. The combined odds ratio (OR) was 1.20 (95%CI: 0.83C 1.73P 0.33), 1.16 (95%CI = 0.74 1.83P 0.52), 0.80 (95%CI = 0.58C 1.10P 0.17). 1.15 (95%CI: 0.662.00); 1.11 (95%CI: 0.761.62); 0.46 (95%CI: 0.131.55); 1.11 (95%CI: 0.761.62); 0.46 (95%CI: 0.131.55; 0.21). Using RevMan5.2 software to draw the inverted funnel graph, all the results except the rate of rebleeding (within 42 days) showed that the graph was basically symmetrical, indicating that the possibility of publication bias was small. The meta analysis, which excluded each study one by one, showed no significant change in aggregate sensitivity and specificity, which indicated that the stability of the literature included was good. Conclusion: there is no significant difference in early hemostasis rate, rebleeding rate, mortality and adverse reaction rate between octreotide group and sclerotherapy group in the treatment of cirrhosis esophageal variceal bleeding. Sclerotherapy is not superior to octreotide in the treatment of esophageal variceal bleeding due to cirrhosis.
【學位授予單位】：吉林大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R575.2

【參考文獻】

相關期刊論文 前10條

1 王建軍;馬大慶;;肝硬化門脈高壓致消化道大出血的介入治療[J];放射學實踐;2007年05期

2 張海月;王魯文;龔作炯;;內(nèi)鏡套扎與普萘洛爾預防肝硬化食管靜脈曲張首次出血效能的Meta分析[J];實用肝臟病雜志;2013年05期

3 吳志勇;張斌;;肝硬化食管胃底靜脈曲張出血的防治[J];肝膽外科雜志;2013年06期

4 令狐恩強;食管胃底靜脈曲張致上消化道出血的內(nèi)鏡下診治[J];中國實用內(nèi)科雜志;2005年03期

5 劉小方;王晨;徐有青;;食管胃靜脈曲張出血的預防和治療[J];胃腸病學和肝病學雜志;2009年04期

6 程留芳;;食管靜脈曲張硬化治療現(xiàn)狀[J];中國消化內(nèi)鏡;2007年02期

7 盧向東;張志廣;;食管胃靜脈曲張出血的治療進展[J];醫(yī)學綜述;2011年03期

8 孔海潛，楊冬華;善得定治療食道靜脈曲張破裂出血的療效評價[J];肝臟病雜志;1995年04期

9 王維民;王歆光;;藥物在防治門靜脈高壓癥上消化道出血中的作用[J];中華外科雜志;2007年13期

10 Natalie Funakoshi;Frédérique Ségalas-Largey;Yohan Duny;Frédéric Oberti;Jean-Christophe Valats;Michael Bismuth;Jean-Pierre Daurès;Pierre Blanc;;Benefit of combination β-blocker and endoscopic treatment to prevent variceal rebleeding: A meta-analysis[J];World Journal of Gastroenterology;2010年47期

本文編號：2350404